Caption Management’s Akero Therapeutics AKRO Stock Holding History

Caption Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,000	Closed	-$1.42M	–	1537
2025 Q3	$1.42M	Sell	30,000 -110,000	-79%	-$5.33M	0.01%	978
2025 Q2	$7.47M	Buy	140,000 +88,000	+169%	+$4M	0.08%	286
2025 Q1	$2.1M	Buy	+52,000	New	+$2.2M	0.02%	664
2024 Q2	–	Sell	-50,000	Closed	-$1.26M	–	1122
2024 Q1	$1.26M	Buy	50,000 +22,600	+82%	+$543K	0.02%	674
2023 Q4	$640K	Sell	27,400 -177,900	-87%	-$3.51M	0.01%	903
2023 Q3	$10.4M	Buy	205,300 +171,200	+502%	+$7.97M	0.16%	152
2023 Q2	$1.59M	Buy	34,100 +4,100	+14%	+$188K	0.03%	564
2023 Q1	$1.15M	Buy	+30,000	New	+$1.34M	0.02%	599
2022 Q4	–	Sell	-106,300	Closed	-$3.62M	–	1247
2022 Q3	$3.62M	Buy	+106,300	New	+$1.63M	0.05%	449

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's AKRO Position: Q4 2025 in Review

Caption Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 39,500 shares — an estimated $1.88M sold.

Caption Management first reported a position in AKRO in Q1 2020 and held it in 11 quarters. The position peaked at $1.88M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Caption Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 39,500 Akero Therapeutics shares in Q4 2025, an estimated $1.88M.
Caption Management first reported a position in Akero Therapeutics in Q1 2020 and held it in 11 quarters.
Caption Management's Akero Therapeutics position peaked at $1.88M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.